Gewinn & Umsatz News zur HUTCHMED Aktie

>HUTCHMED Performance

1 Woche: +7,1%

1 Monat: +4,3%

3 Monate: +12,1%

6 Monate: -6,3%

1 Jahr: -9,1%

laufendes Jahr: +12,1%

>HUTCHMED Aktie

Name:

HUTCHMED (CHINA) LS-,1

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG4672N1198 / A2PJ5B

Symbol/ Ticker:

H7T2 (Frankfurt)

Kürzel:

FRA:H7T2, ETR:H7T2, H7T2:GR

Index:

Webseite:

https://www.hutch-med.com..

Profil:

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company headquartered in Hong Kong, focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunologic..
>Volltext..

Marktkapitalisierung:

2301.81 Mio. EUR

Unternehmenswert:

1233.02 Mio. EUR

Umsatz:

475.88 Mio. EUR

EBITDA:

-22.44 Mio. EUR

Nettogewinn:

396.24 Mio. EUR

Gewinn je Aktie:

0.46 EUR

Schulden:

84.79 Mio. EUR

Liquide Mittel:

61.79 Mio. EUR

Operativer Cashflow:

-56.12 Mio. EUR

Bargeldquote:

4.33

Umsatzwachstum:

-23.48%

Gewinnwachstum:

963.36%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

HUTCHMED

Letzte Datenerhebung:

05.04.26

>HUTCHMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 872.33 Mio. St.

Frei handelbar: 57.66%

Leerverk. Aktien: -

Rückkaufquote: -0.06%

Mitarbeiter: 1796

Umsatz/Mitarb.: 0.26 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 36.56%

Bewertung:

KGV: 6.05

KGV lG: 51.51

KUV: 5.15

KBV: 2.23

PEG-Ratio: 0.01

EV/EBITDA: -

Rentabilität:

Bruttomarge: 38.68%

Gewinnmarge: 83.27%

Operative Marge: -7.14%

Managementeffizenz:

Gesamtkaprendite: 30.25%

Eigenkaprendite: 45.83%

>HUTCHMED Peer Group

Gesundheit, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>HUTCHMED Chart & Kurs - Stuttgart

>HUTCHMED Gewinn & Umsatz News

05.03.26 - 14:03	Hutchmed China Ltd. Full Year Profit Advances (AFX)
	BEIJING (dpa-AFX) - Hutchmed China Ltd. (HCM) released earnings for its full year that Increased, from last yearThe company's earnings came in at $456.909 million, or $0.52 per share. This compare......

14.01.26 - 07:42	HUTCHMED Announces Publication Of Phase III SACHI Study Results In The Lancet (AFX)
	LONDON (dpa-AFX) - HUTCHMED (China) Limited (HCM) on Wednesday said results from the Phase III SACHI trial evaluating savolitinib in combination with osimertinib were published in The Lancet.The S......

07.08.25 - 14:18	Hutchmed China Ltd. Profit Advances In H1 (AFX)
	BEIJING (dpa-AFX) - Hutchmed China Ltd. (HCM.L) revealed earnings for its first half that Increases, from last yearThe company's bottom line totaled $454.95 million, or $0.52 per share. This compa......

02.06.25 - 05:49	HCM: Phase III Study Of Savolitinib Combo Shows Promising Results For EGFR-Mutated NSCLC Treatment (AFX)
	BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) announced that results from the SACHI Phase III study represent a significant advancement in the treatment of EGFR mutation-positive NSCLC with M......

20.03.25 - 05:01	HUTCHMED Highlights Savolitinib SAVANNAH Phase II Results And Additional Key Data (AFX)
	BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) announced positive results from the SAVANNAH Phase II trial, which showed high and durable response rates with the combination of savolitinib and......

19.03.25 - 12:31	HUTCHMED (China) Limited Full Year Profit Drops (AFX)
	BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) released earnings for full year that decreased from the same period last yearThe company's bottom line came in at $37.73 million, or $0.22 per sh......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram